SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. (OTCBB:MCET - News), developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, has posted a scientific article published in the Journal of Immunology on its web site describing the application of the Company’s unique immune system modulation technology to treat cancer.
